Tous les communiqués de presse

all press releases
  • Legend
  • corporate
  • finance
  • sciences
  • Cellectis CEO Selected as Speaker for 2017 Milken Institute Global Conference

    Dr. André Choulika to Serve as Panelist for “Humankind vs. Cancer: The Scorecard”   New York, N.Y. – April 27, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced that the Company’s founder, Chairman and CEO, Dr. André Choulika, has been selected as a speaker for the 2017 Milken Institute Global Conference. Dr. Choulika will participate as a panelist for a session titled, “Humankind vs. Cancer: The Scorecard” on Wednesday, May 3, 2017, at 10 a.m. local time.

    read more download
  • Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting

    New York, N.Y. – April 25, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells, today announced that data on its gene-edited allogeneic off-the-shelf CAR T-cell immunotherapies (UCART) will be presented at the ASGCT 20th Annual Meeting. The meeting will be held from May 10th to 13th, 2017 in Washington, D.C., USA.

    read more download
  • Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.

    April 12, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offering (IPO) of a minority interest in its plant sciences business, Calyxt, Inc. No decisions have been taken at this point on the structure or timing of any IPO, and no assurance can be given that an IPO will be pursued.

    read more download
  • Monthly information on share capital and company voting rights

    read more
  • Corporate Presentation March 2017

    read more

Pages